Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Clovis Oncology Inc (CLVS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,862,231
  • Shares Outstanding, K 52,650
  • Annual Sales, $ 55,510 K
  • Annual Income, $ -346,400 K
  • 36-Month Beta 1.25
  • Price/Sales 33.08
  • Price/Cash Flow N/A
  • Price/Book 5.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.71
  • Number of Estimates 4
  • High Estimate -1.49
  • Low Estimate -1.96
  • Prior Year -1.24
  • Growth Rate Est. (year over year) -37.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.85 +2.98%
on 08/10/18
48.32 -27.86%
on 07/20/18
-11.76 (-25.23%)
since 07/17/18
3-Month
33.85 +2.98%
on 08/10/18
52.15 -33.15%
on 05/18/18
-17.15 (-32.97%)
since 05/17/18
52-Week
33.85 +2.98%
on 08/10/18
86.26 -59.59%
on 10/13/17
-35.01 (-50.11%)
since 08/17/17

Most Recent Stories

More News
IGM Biosciences Appoints Julie Hambleton, M.D., to Board of Directors

IGM Biosciences, Inc. (IGM), a privately held biotechnology company and a global leader in the research and development of therapeutic IgM antibodies, today announced the appointment of Julie Hambleton,...

FPRX : 13.34 (-2.98%)
CLVS : 34.87 (-1.41%)
BMY : 60.90 (-0.34%)
21.4% Return Seen to Date on SmarTrend Clovis Oncology Call (CLVS)

SmarTrend identified a Downtrend for Clovis Oncology (NASDAQ:CLVS) on July 25th, 2018 at $44.69. In approximately 2 weeks, Clovis Oncology has returned 21.44% as of today's recent price of $35.11.

CLVS : 34.87 (-1.41%)
Clovis Oncology Announces First Patient Enrolled in the Phase 3 ATHENA Trial

Clovis Oncology, Inc. (NASDAQ: CLVS) announced today the randomization of the first patient in the Phase 3 ATHENA trial evaluating the combination of Clovis' Rubraca(R) (rucaparib), a ...

CLVS : 34.87 (-1.41%)
Clovis Oncology Set to Possibly Rebound After Yesterday's Selloff of 4.88%

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $35.32 to a high of $38.17. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $37.05...

CLVS : 34.87 (-1.41%)
Clovis (CLVS) Q2 Loss Wider Than Expected, Revenues Beat

Clovis (CLVS) misses bottom-line estimates in the second quarter but beats on the top line. Rubraca sales increase.

CLVS : 34.87 (-1.41%)
TSRO : 28.14 (+3.38%)
RHHBY : 30.1600 (+0.70%)
BMY : 60.90 (-0.34%)
TESARO (TSRO) Misses Earnings and Revenue Estimates in Q2

TESARO (TSRO) misses estimates for both earnings and revenues in the second quarter but beats on revenues. Zejula sales increase.

AZN : 38.23 (+0.71%)
JNJ : 134.03 (+1.17%)
CLVS : 34.87 (-1.41%)
TSRO : 28.14 (+3.38%)
Clovis Oncology (CLVS) Reports Q2 Loss, Tops Revenue Estimates

Clovis (CLVS) delivered earnings and revenue surprises of -40.58% and 1.63%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CLVS : 34.87 (-1.41%)
Clovis Oncology to Announce Second Quarter 2018 Financial Results and Host Webcast Conference Call on August 1

Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its second quarter 2018 financial results on Wednesday, August 1, 2018, after the close of the U.S. financial markets. Clovis' senior management...

CLVS : 34.87 (-1.41%)
SmarTrend Watching for Potential Rebound in Shares of Clovis Oncology After 5.01% Loss

Clovis Oncology (NASDAQ:CLVS) traded in a range yesterday that spanned from a low of $46.06 to a high of $48.40. Yesterday, the shares fell 5.0%, which took the trading range below the 3-day low of $47.13...

CLVS : 34.87 (-1.41%)
Free Technical Research on Clovis Oncology and Three More Biotech Equities

Stock Research Monitor: CLSD, CDXS, and CHRS

CDXS : 14.75 (+1.03%)
CLSD : 6.76 (-3.01%)
CLVS : 34.87 (-1.41%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade CLVS with:

Business Summary

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations....

See More

Key Turning Points

2nd Resistance Point 36.42
1st Resistance Point 35.89
Last Price 34.96
1st Support Level 34.72
2nd Support Level 34.08

See More

52-Week High 86.26
Fibonacci 61.8% 66.24
Fibonacci 50% 60.06
Fibonacci 38.2% 53.87
Last Price 34.96
52-Week Low 33.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar